5 Gastroenterology Headlines You Missed in September 2025

September 2025 delivered several important developments in gastroenterology, spanning new American Gastroenterological Association (AGA) guidelines, US Food and Drug Administration (FDA) news, and expert insights on recent progress in the field.

In the past month, the AGA released its clinical practice guideline on the management of gastroparesis and the FDA approved a subcutaneous (SC) induction regimen of guselkumab (Tremfya) for the treatment of adults with moderately to severely active ulcerative colitis (UC). The 2025 Gastroenterology & Hepatology Advanced Practice Providers (GHAPP) conference also took place this month, offering a plethora of expert insight on key topics in the field.

Check out this September 2025 gastroenterology month in review for a recap of HCPLive’s coverage of the top GU news and research from the past few weeks:

AGA Releases Gastroparesis Clinical Practice Guideline, Highlights Unmet Needs

On September 19, 2025, the AGA released its clinical practice guideline on the management of gastroparesis, offering 12 conditional recommendations for ensuring an accurate diagnosis and identifying evidence-based, effective treatments among the available pharmacologic and procedural interventions for patients with idiopathic gastroparesis or gastroparesis related to diabetes.

Related: Controversy and Clarity in New AGA Gastroparesis Guidelines, With Kyle Staller, MD, MPH

FDA Approves Guselkumab (Tremfya) Subcutaneous Induction Regimen for Ulcerative Colitis

On September 19, 2025, the FDA approved a SC induction regimen of guselkumab (Tremfya) for the treatment of adults with moderately to severely active UC, making guselkumab the first and only IL-23 inhibitor to offer both SC and intravenous (IV) induction options for the treatment of UC and Crohn’s disease.

Related: Guselkumab Subcutaneous Induction Advances Ulcerative Colitis Care, With David Rubin, MD

Closing the Gaps in Colon Cancer Screening, With Gabriella McCarty, NP

Colon cancer remains one of the most preventable yet least prevented cancers. Despite advances in screening, uptake across the US remains suboptimal, with no state yet meeting the American Cancer Society’s national goal of screening 80% of eligible adults and an estimated 60 million US adults remaining unscreened. In this interview with HCPLive, Gabriella McCarty, NP, describes advances in and barriers to proper screening, emphasizing the importance of early detection for improving outcomes.

Updates in Eosinophilic GI Disease Management, With Amy Stewart, NP

Eosinophilic GI diseases are gaining greater attention as both recognition and understanding of these conditions expand. Eosinophilic esophagitis (EoE) remains among the most well-studied, with new 2025 American College of Gastroenterology EoE Clinical Guidelines drawing additional attention, as reviewed by Amy Stewart, NP, in this HCPLive interview.

Shared Decision Making in Crohn’s Disease Management, With Jamie Brogan, NP

The treatment landscape for CD has expanded rapidly, most recently with the US Food and Drug Administration approvals of guselkumab (Tremfya) and mirikizumab (Omvoh), bringing new opportunities for improved outcomes but also greater complexity in clinical decision-making. With more therapies available, clinicians must balance efficacy, safety, lifestyle considerations, and patient preferences to guide individualized care, as described by Jamie Brogan, NP, in this HCPLive interview.